Navigation Links
UPCOMING DEADLINE: Levi & Korsinsky, LLP Announces Class Action Against ARIAD Pharmaceuticals, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of December 9, 2013 -- ARIA
Date:12/5/2013

NEW YORK, Dec. 5, 2013 /PRNewswire/ -- Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of investors who purchased ARIAD Pharmaceuticals, Inc. ("ARIAD" or the "Company") (NASDAQ GS: ARIA) stock between December 12, 2011 and October 8, 2013. The Complaint alleges that throughout the Class Period defendants made false and misleading statements regarding the safety and efficacy of the leukemia drug Iclusig.

(Logo:  http://photos.prnewswire.com/prnh/20120409/MM84375LOGO)

For more information, click here: http://zlk.9nl.com/ariad-pharmaceuticals-aria.

On October 9, 2013, ARIAD announced that its leukemia drug Iclusig causes more side effects than previously reported; the Company also announced it would halt enrollment in its clinical trials and instruct current Iclusig users to lower their dosage. The Company disclosed that serious arterial thrombosis occurred in 11.8% of Iclusig-treated patients, and that 6.2% of the patients had cerebrovascular events. On this news, ARIAD shares declined $11.31 per share to close at $5.83 per share on October 9, 2013.

If you suffered a loss in ARIAD you have until December 9, 2013 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/ariad-pharmaceuticals-aria

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut, and Washington D.C.  The firm has extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits.  Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:    
Levi & Korsinsky, LLP
Joseph Levi, Esq.
Eduard Korsinsky, Esq.
30 Broad Street - 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free:  (877) 363-5972
Fax: (212) 363-7171
www.zlk.com


'/>"/>
SOURCE Levi & Korsinsky, LLP
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Regeneron Announces Upcoming 2013 Investor Conference Presentation
2. Organovo Provides Guidance on Upcoming Retail Investor Conference
3. Ampio Pharmaceuticals to Present at Upcoming Investor Conference
4. Amgen To Webcast Investor Meeting At Upcoming American Heart Association Scientific Sessions 2013
5. Preliminary Financial Results, Quarterly Reports and Upcoming Conference Schedules - Research Report on Avanir, BioScrip, Chemed, Foundation Medicine, and Antares
6. ViroPharma Announces Upcoming Data Presentations at the 2013 American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting
7. Orexigen Therapeutics Announces Date of Third Quarter 2013 Financial Results Conference Call and Upcoming Presentation at Credit Suisse Healthcare Conference
8. Alimera Sciences to Release Third Quarter 2013 Results and Provide Update on Upcoming FDA Advisory Committee Meeting
9. Epizyme, Inc. to Present at Upcoming Conferences in November
10. Volcano Announces Upcoming Data Presentations from Large-Scale Studies on Physiology and Imaging Technologies at TCT 2013
11. Healthcare Sector Announced Clinical Data Presentation, Upcoming Financial Release Schedules and Updates on New Drug Applications - Research Report on Alexion, Pacira, pSivida, Momenta and Impax
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... de 2016  A Mederi Therapeutics Inc . anunciou aprovação regulatória, pela ... para a doença do refluxo gastroesofágico (DRGE). Foto -  http://photos.prnewswire.com/prnh/20161207/446903 ... ... Live Stretta procedure performed and broadcast during the Chinese Congress of ... , , ...
(Date:12/8/2016)... Pa. , Dec. 8, 2016  Pennsylvania ... Secretary of Drug and Alcohol Programs Gary ... and insomnia medications, known as benzodiazepines, developed with ... "Benzodiazepines are medications that are frequently prescribed ... when they are used with opioid pain medications, ...
(Date:12/8/2016)... 2016 True Health Diagnostics today announced ... services and management expertise to hospital systems throughout ... more doctors and patients to benefit from state-of-the-art ... Logo - http://photos.prnewswire.com/prnh/20161208/447162LOGO ... pressure to contain costs, have struggled to keep ...
Breaking Medicine Technology:
(Date:12/10/2016)... ... December 10, 2016 , ... ... Santa are all sources of external stimuli that can put a great deal ... pressure to spread holiday cheer through gifts, food and festive gatherings can lead ...
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... ... counseling and aural rehabilitation—provided by audiologists—to remain a critical part of public access ... and Drug Administration (FDA) announced this week that, starting immediately, it ...
(Date:12/9/2016)... ... , ... The Justin Veatch Fund announced Thursday that The ... Whispering Spirits and its discussion guide for use by all of its ... the war against teen drug abuse. NCADD is the oldest anti-addiction advocacy organization ...
(Date:12/9/2016)... ... December 09, 2016 , ... MEDI+SIGN®, a provider ... that a new solution for Emergency Departments (ED) has been added to their ... Emergency Department examination rooms, and with a simplified pallet of information available to ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... Compensation Research Institute (WCRI) officially opened registration today for its 33rd Annual ... in Boston, MA . , The theme of the conference is “Persistent Challenges ...
Breaking Medicine News(10 mins):